Access to drug funding in Canada
Towards an efficient, fair, safe, ethical and simple system
Emily Andrews and Susan Usher
More>>

Maintenance therapy in
advanced NSCLC
Encouraging approaches
Roger Y. Tsang, MD, FRCPC and Charles A. Butts, MD, FRCPC
More>>

The effects of androgen
deprivation on intimacy
Early interventions to minimize
emotional suffering
Lauren M. Walker, BA and John W. Robinson, PhD, RPsych La
More>>

Five-year experience of McGill’s Adolescent and Young Adult Program
Challenges and successes
Michael Palumbo, MD, PhD, Petr Kavan, MD, PhD et al
More>>

We welcome your letters and suggestions for future articles.

Please address correspondence to Emily Andrews, Managing Editor, at andrews@parkpub.com

Review of important clinical trials with commentaries by Canadian experts
The 50th American Society of Hematology Annual Meeting
Tyrosine kinase inhibitors in early chronic phase CML
A. Robert Turner MD, FRCPC
Rituximab added to standard therapy in advanced CLL
Pentostatin replacing fludarabine in early CLL
Flavopiridol in relapsed CLL
Loree Larratt, MD, FRCPC
More>>

The growing role of private sector payment for cancer care
Kong Khoo, MD, FRCPC
More>>

Selected abstracts from the 2009 Annual Meeting of CAMO
More>>

Controlling nausea and vomiting in patients undergoing chemotherapy
Toward more effective clinical practice
David Warr, MD, FRCPC and Carlo DeAngelis, PharmD
More>>